drugset / Trial / NCT05804526
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
NaSequentialOpen-labelTreatment
Summary
This study will evaluate safety , clinical pharmacology and efficacy of intravenous RC88 combined with Sintilimab in advancedsolid tumours
Timeline
- Start
- 2023-07-19
- Primary completion
- 2025-05
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC88 | Unknown | 1.5 mg/kg | Intravenous |
| Subject | RC88 | Unknown | 2 mg/kg | Intravenous |
| Subject | RC88 | Unknown | 2.5 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |